The prevention and regression of atherosclerotic plaques: Emerging treatments

Vascular Health and Risk Management

Volumn 8, Issue 1, 2012, Pages 549-561

  Kalanuria, Atul Ashok ^a   Nyquist, Paul ^a   Ling, Geoffrey ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center   (United States)

Author keywords

Atherosclerotic disease; Cardiovascular; Coronary artery disease; Endothelium; Plaque; Reversal; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ANACETRAPIB; ANTIBIOTIC AGENT; ANTIOXIDANT; ATORVASTATIN; CILOSTAZOL; CLOPIDOGREL; DALCETRAPIB; DIPYRIDAMOLE; ESTRADIOL; ETIDRONIC ACID; EZETIMIBE; GLIPIZIDE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAROPIPRANT; LOW DENSITY LIPOPROTEIN; NICOTINIC ACID; PIOGLITAZONE; PITAVASTATIN; PLACEBO; PRASUGREL; PRAVASTATIN; PROBUCOL; RAMIPRIL; ROSIGLITAZONE; ROSUVASTATIN; TICAGRELOR; TORCETRAPIB; UNINDEXED DRUG; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; ESTROGEN; NITROUS OXIDE; PROSTACYCLIN;

ATHERECTOMY; ATHEROSCLEROTIC PLAQUE; BARE METAL STENT; BRAIN HEMORRHAGE; BYPASS SURGERY; CAROTID ANGIOPLASTY; CAROTID ARTERY STENTING; CAROTID ENDARTERECTOMY; CHLAMYDIAL PNEUMONIA; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CORONARY RISK; DIET THERAPY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; ENDOTHELIUM LESION; HEART PROTECTION; HEART REHABILITATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; INTRAVASCULAR ULTRASOUND; KINESIOTHERAPY; LIFESTYLE MODIFICATION; LIPID PEROXIDATION; LOADING DRUG DOSE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PRIMARY PREVENTION; PROTEIN FUNCTION; REVIEW; RISK ASSESSMENT; SCREENING TEST; SECONDARY PREVENTION; SEDENTARY LIFESTYLE; SMOKING CESSATION; UNSPECIFIED SIDE EFFECT; ATHEROSCLEROSIS; DIAGNOSTIC IMAGING; DIET; DISEASE COURSE; EXERCISE; MASS SCREENING;

ANTIOXIDANTS; ATHEROSCLEROSIS; DIAGNOSTIC IMAGING; DIET; DISEASE PROGRESSION; EPOPROSTENOL; ESTROGENS; EXERCISE; HUMANS; HYPOLIPIDEMIC AGENTS; MASS SCREENING; NITROUS OXIDE; PLATELET AGGREGATION INHIBITORS; PRIMARY PREVENTION; SECONDARY PREVENTION;

EID: 84874814357     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S27764     Document Type: Review

References (82)

1. Roger VL, Go AL, Lloyd-Jones DM, et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Executive summary: heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation. 2012;125:188-197.
2. Heidenreich PA, Trogdon JG, Khavjou OA, et al. American Heart Association Advocacy Coordinating Committee; Stroke Council; Council on Cardiovascular Radiology and Intervention; Council on Clinical Cardiology; Council on Epidemiology and Prevention; Council on Arteriosclerosis; Thrombosis and Vascular Biology; Council on Cardiopulmonary; Critical Care; Perioperative and Resuscitation; Council on Cardiovascular Nursing; Council on the Kidney in Cardiovascular Disease; Council on Cardiovascular Surgery and Anesthesia, and Interdisciplinary Council on Quality of Care and Outcomes Research. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation. 2011;123(8):933-944.
3. Mallika V, Goswami B, Rajappa M. Atherosclerosis pathophysiology and the role of novel risk factors: a clinicobiochemical perspective. Angiology. 2007;58(5):513-522.
4. Fleming RM. The effect of high-, moderate-, and low-fat diets on weight loss and cardiovascular disease risk factors. Prev Cardiol. 2002;5(3):10-118.
5. Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: testing and clinical relevance. Circulation. 2007;115(10):1285-1295.
6. Tousoulis D, Kampoli AM, Tentolouris C, Papageorgiou N, Stefanadis C. The role of nitric oxide on endothelial function. Curr Vasc Pharmacol. 2012;10(1):4-18.
7. Shah PK. Molecular mechanisms of plaque instability. Curr Opin Lipidol. 2007;18(5):492-499.
8. Calabresi L, Simonelli S, Gomaraschi M, Franceschini G. Genetic lecithin:cholesterol acyltransferase deficiency and cardiovascular disease. Atherosclerosis. 2012;222(2):299-306.
9. Sanz J, Moreno PR, Fuster V. The year in atherothrombosis. J Am Coll Cardiol. 2009;53(15):1326-1337.
10. Falk E. Pathogenesis of atherosclerosis. J Am Coll Cardiol. 2006;47 (Suppl 8):C7-C12.
11. Stone GW, Maehara A, Lansky AJ, et al. PROSPECT Investigators. A prospective natural-history study of coronary atherosclerosis. N Engl J Med. 2011;364(3):226-235.
12. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr. Carotid artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med. 1999;340(1):14-22.
13. Kavey RE, Daniels SR, Lauer RM, Atkins DL, Hayman LL, Taubert K; American Heart Association. American Heart Association guidelines for primary prevention of atherosclerotic cardiovascular disease beginning in childhood. Circulation. 2003;107(11):1562-1566.
14. Greenland P, Alpert JS, Beller GA, et al. American College of Cardiology Foundation; American Heart Association. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2010;56(25):e50-e103.
15. Gidding SS, Lichtenstein AH, Faith MS, et al. Implementing American Heart Association pediatric and adult nutrition guidelines: a scientific statement from the American Heart Association Nutrition Committee of the Council on Nutrition, Physical Activity and Metabolism, Council on Cardiovascular Disease in the Young, Council on Arteriosclerosis, Thrombosis and Vascular Biology, Council on Cardiovascular Nursing, Council on Epidemiology and Prevention, and Council for High Blood Pressure Research. Circulation. 2009;119(8):1161-1175.
16. Zeb I, Budoff MJ. MESA: The NIH-sponsored study that validates atherosclerosis imaging for primary prevention. Curr Atheroscler Rep. 2011;13(5):353-358.
17. Naghavi M, Falk E, Hecht HS, et al. SHAPE Task Force. From vulnerable plaque to vulnerable patient-Part III: Executive summary of the Screening for Heart Attack Prevention and Education (SHAPE) Task Force report. Am J Cardiol. 2006;98(2A):2H-15H.
18. Aguilar-Shea AL, Gallardo-Mayo C, Garrido-Elustondo S, Calvo-Manuel E, Zamorano-Gómez JL. Carotid intima-media thickness as a screening tool in cardiovascular primary prevention. Eur J Clin Invest. 2011;41(5):521-526.
19. Hecht HS. The role of atherosclerosis imaging in redefining normal and abnormal cholesterol values, and risk reduction in primary prevention statin trials. Curr Atheroscler Rep. 2011;13(5):422-430.
20. Lenfant F, Trémollières F, Gourdy P, Arnal JF. Timing of the vascular actions of estrogens in experimental and human studies: why protective early, and not when delayed? Maturitas. 2011;68(2):165-173.
21. Deniset JF, Pierce GN. Possibilities for therapeutic interventions in disrupting Chlamydophila pneumoniae involvement in atherosclerosis. Fundam Clin Pharmacol. 2010;24(5):607-617.
22. Pashkow FJ. Oxidative Stress and Inflammation in Heart Disease: Do Antioxidants Have a Role in Treatment and/or Prevention? Int J Inflam. 2011;2011:514-623.
23. Reis JP, Loria CM, Steffen LM, et al. Coffee, decaffeinated coffee, caffeine, and tea consumption in young adulthood and atherosclerosis later in life: the CARDIA study. Arterioscler Thromb Vasc Biol. 2010;30(10): 2059-2066.
24. Muntendam P, McCall C, Sanz J, Falk E, Fuster V; High-Risk Plaque Initiative. The BioImage Study: novel approaches to risk assessment in the primary prevention of atherosclerotic cardiovascular disease-study design and objectives. Am Heart J. 2010;160(1):49-57.
25. Dauchet L, Amouyel P, Dallongeville J. Fruits, vegetables and coronary heart disease. Nat Rev Cardiol. 2009;6(9):599-608.
26. 1c, nitric oxide and total antioxidant status in diabetic patients with atherosclerotic peripheral arterial disease of lower extremities. Eur Rev Med Pharmacol Sci. 2012;16(3):342-350.
27. Szostak J, Laurant P. The forgotten face of regular physical exercise: a "natural" anti-atherogenic activity. Clin Sci (Lond). 2011;121(3):91-106.
28. Ahmed HM, Blaha MJ, Nasir K, Rivera JJ, Blumenthal RS. Effects of physical activity on cardiovascular disease. Am J Cardiol. 2012;109(2): 288-295.
29. Ford MA, Allison TG, Lerman A. New approaches to the concept of primary prevention of atherosclerosis. Curr Treat Options Cardiovasc Med. 2008;10(1):73-82.
30. Smith SC Jr, Benjamin EJ, Bonow RO et al. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation. 2011 Nov 29;124(22):2458-2473.
31. Smith SC Jr, Benjamin EJ, Bonow RO, et al; World Heart Federation and the Preventive Cardiovascular Nurses Association. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation. 2011;124(22):2458-2473.
32. Lichtman JH, Bigger JT Jr, Blumenthal JA, et al. American Heart Association Prevention Committee of the Council on Cardiovascular Nursing; American Heart Association Council on Clinical Cardiology; American Heart Association Council on Epidemiology and Prevention; American Heart Association Interdisciplinary Council on Quality of Care and Outcomes Research; American Psychiatric Association. Depression and coronary heart disease: recommendations for screening, referral, and treatment: a science advisory from the American Heart Association Prevention Committee of the Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Psychiatric Association. Circulation. 2008;118(17):1768-1775.
33. Leon AS, Franklin BA, Costa F, et al; American Heart Association; Council on Clinical Cardiology (Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention); Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity); American association of Cardiovascular and Pulmonary Rehabilitation. Cardiac rehabilitation and secondary prevention of coronary heart disease: an American Heart Association scientific statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity), in collaboration with the American association of Cardiovascular and Pulmonary Rehabilitation. Circulation. 2005;111(3):369-376.
34. Brott TG, Halperin JL, Abbara S, et al; American College of Cardiology Foundation; American Stroke Association; American Association of Neurological Surgeons; American College of Radiology; American Society of Neuroradiology; Congress of Neurological Surgeons; Society of Atherosclerosis Imaging and Prevention; Society for Cardiovascular Angiography and Interventions; Society of Interventional Radiology; Society of NeuroInterventional Surgery; Society for Vascular Medicine; Society for Vascular Surgery. 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease: executive summary. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American Stroke Association, American Association of Neuroscience Nurses, American Association of Neurological Surgeons, American College of Radiology, American Society of Neuroradiology, Congress of Neurological Surgeons, Society of Atherosclerosis Imaging and Prevention, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of NeuroInterventional Surgery, Society for Vascular Medicine, and Society for Vascular Surgery. Circulation. 2011;124(4):489-532.
35. Wallentin L, Becker RC, Budaj A, et al; PLATO Investigators, Freij A, Thorsén M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045-1057.
36. Wiviott SD, Braunwald E, McCabe CH, et al; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001-2015.
37. Gerstein HC, Ratner RE, Cannon CP, et al; APPROACH Study Group. Effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease: the assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history trial. Circulation. 2010;121(10):1176-1187.
38. García-García HM, Garg S, Brugaletta S, et al; APPROACH study group. Evaluation of in-stent restenosis in the APPROACH trial (assessment on the prevention of progression by Rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history). Int J Cardiovasc Imaging. 2012;28(3):455-465.
39. Francis AA, Pierce GN. An integrated approach for the mechanisms responsible for atherosclerotic plaque regression. Exp Clin Cardiol. 2011;16(3):77-86.
40. Bedi U, Singh M, Singh P, Molnar J, Khosla S, Arora R. Effects of statins on progression of coronary artery disease as measured by intravascular ultrasound. J Clin Hypertens (Greenwich). 2011;13(7): 492-496.
41. Han SH, Chung WJ, Kang WC, et al. Rosuvastatin combined with ramipril significantly reduced atheroma volume by anti-inflammatory mechanism: Comparative analysis with rosuvastatin alone by intravascular ultrasound. Int J Cardiol. 2012;158(2):217-224.
42. Takayama T, Hiro T, Yamagishi M, et al; COSMOS Investigators. Effect of rosuvastatin on coronary atheroma in stable coronary artery disease: multicenter coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS). Circ J. 2009;73(11):2110-2117.
43. Hibi K, Kimura T, Kimura K, et al; JAPAN-ACS Investigators. Clinically evident polyvascular disease and regression of coronary atherosclerosis after intensive statin therapy in patients with acute coronary syndrome: serial intravascular ultrasound from the Japanese assessment of pitavastatin and atorvastatin in acute coronary syndrome (JAPAN-ACS) trial. Atherosclerosis. 2011;219(2):743-749.
44. Arai H, Hiro T, Kimura T, et al; JAPAN-ACS Investigators. More intensive lipid lowering is associated with regression of coronary atherosclerosis in diabetic patients with acute coronary syndrome-sub-analysis of JAPAN-ACS study. J Atheroscler Thromb. 2010;17(10):1096-1107.
45. Hong YJ, Jeong MH, Hachinohe D, et al. Comparison of Effects of rosuvastatin and atorvastatin on plaque regression in Korean patients with untreated intermediate coronary stenosis. Circ J. 2011;75(2): 398-406.
46. Tani S, Nagao K, Anazawa T, et al. Relation of change in apolipoprotein B/apolipoprotein A-I ratio to coronary plaque regression after Pravastatin treatment in patients with coronary artery disease. Am J Cardiol. 2010;105(2):144-148.
47. Kawahara T, Nishikawa M, Furusawa T, Inazu T, Suzuki G. Effect of atorvastatin and etidronate combination therapy on regression of aortic atherosclerotic plaques evaluated by magnetic resonance imaging. J Atheroscler Thromb. 2011;18(5):384-395.
48. Ko YG, Kim BK, Lee BK, et al. SECURE Investigators. Study design and rationale of "Synergistic effect of combination therapy with cilostazol and ProbUcol on plaque stabilization and lesion REgression (SECURE)" study: a double-blind randomised controlled multicenter clinical trial. Trials. 2011;12:10.
49. Kovarnik T, Mintz GS, Skalicka H, et al. Virtual histology evaluation of atherosclerosis regression during atorvastatin and ezetimibe administration: HEAVEN study. Circ J. 2012;76(1):176-183.
50. Migrino RQ, Bowers M, Harmann L, Prost R, LaDisa JF Jr. Carotid plaque regression following 6-month statin therapy assessed by 3T cardiovascular magnetic resonance: comparison with ultrasound intima media thickness. J Cardiovasc Magn Reson. 2011;13:37.
51. Nicholls SJ, Ballantyne CM, Barter PJ, et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med. 2011; 365(22):2078-2087.
52. Nicholls SJ, Tuzcu EM, Sipahi I, et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA. 2007; 297(5):499-508.
53. Yang HB, Zhao XY, Zhang JY, Du YY, Wang XF. Pioglitazone induces regression and stabilization of coronary atherosclerotic plaques in patients with impaired glucose tolerance. Diabet Med. 2012;29(3):359-365.
54. Nakayama T, Komiyama N, Yokoyama M, et al. Pioglitazone induces regression of coronary atherosclerotic plaques in patients with type 2 diabetes mellitus or impaired glucose tolerance: a randomized prospective study using intravascular ultrasound. Int J Cardiol. 2010;138(2):157-165.
55. Clementi F, Di Luozzo M, Mango R, et al. Regression and shift in composition of coronary atherosclerotic plaques by pioglitazone: insight from an intravascular ultrasound analysis. J Cardiovasc Med (Hagerstown). 2009;10(3):231-237.
56. Kadoglou NP, Sailer N, Moumtzouoglou A, Kapelouzou A, Gerasimidis T, Liapis CD, et al. Aggressive lipid-lowering is more effective than moderate lipid-lowering treatment in carotid plaque stabilization. J Vasc Surg. 2010;51(1):114-121.
57. Shai I, Spence JD, Schwarzfuchs D, et al; DIRECT Group. Dietary intervention to reverse carotid atherosclerosis. Circulation. 2010;121(10): 1200-1208.
58. Godin B, Sakamoto JH, Serda RE, Grattoni A, Bouamrani A, Ferrari M. Emerging applications of nanomedicine for therapy and diagnosis of cardiovascular diseases. Trends Pharmacol Sci. 2010;31(5):199-205.
59. Lobatto ME, Fuster V, Fayad ZA, Mulder WJ. Perspectives and opportunities for nanomedicine in the management of atherosclerosis. Nat Rev Drug Discov. 2011;10(11):835-852.
60. O'Neil CP, van der Vlies AJ, Velluto D, et al. Extracellular matrix binding mixed micelles for drug delivery applications. J Control Release. 2009;137(2):146-151.
61. Chan JM, Zhang L, Tong R, et al. Spatiotemporal controlled delivery of nanoparticles to injured vasculature. Proc Natl Acad Sci U S A. 2010; 107(5):2213-2218.
62. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med. 1977;62(5):707-714.
63. Sharrett AR, Ballantyne CM, Coady SA, et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2001;104(10):1108-1113.
64. Forrester JS, Shah PK. Emerging strategies for increasing high-density lipoprotein. Am J Cardiol. 2006;98(11):1542-1549.
65. Fayad ZA, Mani V, Woodward M, et al; dal-PLAQUE Investigators. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet. 2011;378(9802):1547-1559.
66. Boettcher MF, Heinig R, Schmeck C, et al. Single dose pharmacokinetics, pharmacodynamics, tolerability and safety of BAY 60-5521, a potent inhibitor of cholesteryl ester transfer protein. Br J Clin Pharmacol. 2012;73(2):210-218.
67. Gutstein DE, Krishna R, Johns D, et al. Anacetrapib, a novel CETP inhibitor: pursuing a new approach to cardiovascular risk reduction. Clin Pharmacol Ther. 2012;91(1):109-122.
68. Cannon CP, Dansky HM, Davidson M, et al; DEFINE investigators. Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib. Am Heart J. 2009;158(4): 513-519.e3.
69. Chen F, Maccubbin D, Yan L, et al. Lipid-altering efficacy and safety profile of co-administered extended release niacin/laropiprant and simvastatin versus atorvastatin in patients with mixed hyperlipidemia. Int J Cardiol. 2012. Epub Feb 3.
70. Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation. 2004;110(23):3512-3517.
71. Villines TC, Stanek EJ, Devine PJ, et al. The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration. J Am Coll Cardiol. 2010;55(24):2721-2726.
72. Yadav R, France M, Younis N, et al. Extended-release niacin with laropiprant: a review on efficacy, clinical effectiveness and safety. Expert Opin Pharmacother. 2012;13(9):1345-1362.
73. University of Oxford. Treatment of HDL to reduce the incidence of vascular events HPS2-THRIVE. In: ClinicalTrials.gov [website on the Internet]. Bethseda, MD: US National Library of Medicine; 2007 [updated July 19, 2010]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00461630.NLMidentifier:NCT00461630. Accessed July 5, 2012.
74. University of Washington. Carotid plaque characteristics by MRI in AIM-HIGH (Carotid MRI Substudy). In: ClinicalTrials.gov [website on the Internet]. Bethseda, MD: US National Library of Medicine; 2010 [updated June 19, 2012]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01178320.NLMidentifier:NCT01178320. Accessed July 5, 2012.
75. National Heart, Lung, and Blood Institute. Plaque inflammation and dysfunctional hdl cholesterol in participants receiving niacin and statins in the AIM-HIGH Study (The HDL Proteomics Study). In: ClinicalTrials.gov [website on the Internet]. Bethseda, MD: US National Library of Medicine; 2009 [updated February 23, 2012]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00880178.NLM identifier:NCT00880178. Accessed July 5, 2012.
76. Buse JB, Rubin CJ, Frederich R, et al. Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes. Clin Ther. 2005;27(8):1181-1195.
77. Goldstein BJ, Rosenstock J, Anzalone D, Tou C, Ohman KP. Effect of tesaglitazar, a dual PPAR alpha/gamma agonist, on glucose and lipid abnormalities in patients with type 2 diabetes: a 12-week dose-ranging trial. Curr Med Res Opin. 2006;22(12):2575-2590.
78. Saad MF, Greco S, Osei K, et al; Ragaglitazar Dose-Ranging Study Group. Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic subjects: a 12-week, double-blind, placebo-controlled dose-ranging study with an open pioglitazone arm. Diabetes Care. 2004;27(6):1324-1329.
79. Tardif JC, Grégoire J, L'Allier PL, et al; Effect of rHDL on Atherosclerosis-Safety and Efficacy (ERASE) Investigators. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA. 2007;97(15):1675-1682.
80. Waksman R, Torguson R, Kent KM, et al. A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome. J Am Coll Cardiol. 2010;55(24): 2727-2735.
81. Cerenis Therapeutics, SA. Effect of CER-001 on atherosclerosis in acute coronary syndrome (ACS) patients-efficacy and safety: the CHI SQUARE Trial. In: ClinicalTrials.gov [website on the Internet]. Bethseda, MD: US National Library of Medicine; 2010 [updated June 14, 2012]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01201837.NLMidentifier:NCT01201837. Accessed July 5, 2012.
82. Resverlogix Corp. National Institute of Health ApoA-I synthesis stimulation and intravascular ultrasound for coronary atheroma regression evaluation. In: ClinicalTrials.gov [website on the Internet]. Bethseda, MD: US National Library of Medicine; 2010 [updated June 27, 2012]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01067820.NLM identifier:NCT01067820. Accessed July 5, 2012.